OrthoPediatrics Earnings Call Flags Profitable Turn

Orthopediatrics Corp ((KIDS)) has held its Q4 earnings call. Read on for the main highlights of the call.

OrthoPediatrics Corp’s latest earnings call struck an optimistic tone, with management emphasizing a clear financial inflection. Revenue growth accelerated, margins expanded, and the company delivered its first quarter of positive free cash flow. While losses and spending remain elevated, executives framed them as investments behind a robust product pipeline and credible 2026 profitability goals.

Revenue Growth Highlights Strong Demand

Q4 2025 revenue reached $61.6 million, up 17% year over year, capping full‑year growth of 15%. Management reaffirmed its 2026 revenue outlook of $262–$266 million, implying 11%–13% annual growth and signaling confidence that current momentum can be sustained.

Margins Expand and Profitability Improves

Gross margin climbed to 73% in Q4 from 68% a year earlier, reflecting better mix and operating leverage. Adjusted EBITDA rose to $4.8 million, up 59% year over year, with nearly 75% full‑year growth and a path toward roughly $25 million of adjusted EBITDA in 2026 at similar gross margins.

Free Cash Flow Turns Positive

The company generated $10 million in free cash flow in Q4, its first positive quarter, marking a key financial milestone. For 2025, cash usage narrowed to $15 million from $41 million in 2024, while cash and investments ended the year at $62.9 million, bolstering liquidity.

Segment Strength Across Core Franchises

Trauma & Deformity revenue rose 17% to $42.6 million in Q4, while Scoliosis grew 13% to $17.6 million, underscoring broad-based demand. The specialty bracing business (OPSB) continued to act as a growth engine, with same-store gains, faster‑than‑planned clinic expansion, and several new brace launches.

Innovation Pipeline Fuels Growth Story

Management highlighted a “multiyear super cycle” of product innovation, including launches like the 3P Hip, 3P Small‑Mini, PNP tibia and femur systems, PNP Retro and VerteGlide. Early clinical feedback on VerteGlide has been positive, and the EE electromechanical growing spine system is approaching first-in-human use, reinforcing the long‑term growth narrative.

International Business Rebounds

International revenue jumped 33% to $13.0 million in Q4, now 21% of total sales, signaling a strong rebound outside the U.S. The company secured EU MDR approvals for multiple Trauma & Deformity and scoliosis products and X6 devices, and it acquired Brazilian distributor Follow Med to strengthen operations and collections in that key market.

Operational Execution Underpins Guidance

Set deployment increased to $4.5 million in Q4 from $3.7 million a year ago, supporting future procedure volume. Management tied this execution to reiterated 2026 goals for free cash flow breakeven, about $25 million in adjusted EBITDA, and roughly $10 million in annual set deployment.

Losses Narrow but Still Weigh on Results

GAAP net loss per share improved to $0.43 from $0.69 in the prior‑year quarter, yet the company remains unprofitable. On a non‑GAAP basis, loss per share was $0.30 versus $0.29 a year earlier, underscoring that earnings progress is primarily visible in EBITDA and cash flow rather than bottom‑line net income.

Operating Expenses Rise, Led by G&A

Total operating expenses increased 7% to $53.3 million in Q4, reflecting growth investments and higher non‑cash costs. General and administrative spending jumped 23% to $30.0 million, driven by headcount, stock‑based compensation, depreciation and amortization, and a $2.4 million trademark impairment.

R&D Timing Clouds Near-Term Visibility

Research and development expense declined by $0.7 million in Q4 and was down year over year, which management attributed to timing of third‑party work. While executives stressed that the innovation pipeline remains strong, the dip raises questions about the cadence of R&D outlays and future product introductions.

New Platforms Still Early and Small

Digital tools such as Playbook, 7D navigation placements and iotaMotion are in early commercialization phases and contribute modest revenue today. Management noted that these initiatives are not meaningfully embedded in the 2026 outlook, and 7D has faced slower‑than‑hoped implementation and paperwork cycles.

Seasonality Drives Cash Flow Swings

The company warned that quarterly cash flow will remain volatile, with a pattern similar to 2025 in which Q1 is softer and Q3 strongest. Management expects negative free cash flow in the first half of 2026 and positive in the second half, relying on back‑half strength to hit full‑year breakeven.

U.S. Concentration and Competitive Pressures

U.S. sales accounted for 79% of Q4 revenue, highlighting geographic concentration risk and reliance on domestic trends. In scoliosis, management acknowledged competition from larger spine companies even as it reports share gains, underlining an ongoing battle to defend and grow its niche.

Guidance Signals Confidence in 2026 Inflection

Management reaffirmed 2026 targets for $262–$266 million in revenue, roughly $25 million of adjusted EBITDA, and free‑cash‑flow breakeven, supported by steady gross margins near 73%. They expect set deployment of around $10 million and reiterated that seasonality will skew cash generation to the back half, building on Q4’s strong revenue, margin and cash‑flow performance.

OrthoPediatrics’ call painted the picture of a business turning an important corner, with strong growth, expanding margins and a first taste of positive free cash flow. Investors still must weigh ongoing losses, heavier spending and competitive threats, but management’s confidence in its product cycle and 2026 targets suggests a favorable risk‑reward for long‑term growth-focused shareholders.